Aviceda Therapeutics

Executive Summary

Aviceda Therapeutics is a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for retinal diseases, with a primary focus on geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company's lead platform employs glycan-coated nanoparticles designed to selectively modulate the innate immune system within the eye, aiming to halt disease progression while minimizing systemic side effects. Founded in 2019 and headquartered in Cambridge, MA, Aviceda has raised over $207 million in total funding, reflecting strong investor confidence. The company is currently advancing its lead candidate through Phase 2 clinical trials, targeting a large and underserved patient population. With no approved therapies that directly address the underlying immune dysfunction in GA, Aviceda's differentiated mechanism of action and robust financial backing position it as a potentially transformative player in the ophthalmic immunology space. Key upcoming milestones include data readouts from ongoing trials, which will be critical for validating the platform and driving further development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead candidate in geographic atrophy50% success
• H1 2027Potential partnership or out-licensing deal for non-core indications40% success
• H2 2026Series D or crossover financing round70% success